| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.PNPBP.2007.09.015 |
| P698 | PubMed publication ID | 17976882 |
| P50 | author | Veiko Vasar | Q19624452 |
| Jakov Shlik | Q60580936 | ||
| Eduard Maron | Q60581649 | ||
| P2093 | author name string | Triin Eller | |
| P433 | issue | 2 | |
| P921 | main subject | escitalopram | Q423757 |
| P304 | page(s) | 445-450 | |
| P577 | publication date | 2007-09-26 | |
| P1433 | published in | Progress in Neuro-Psychopharmacology & Biological Psychiatry | Q15616665 |
| P1476 | title | Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder | |
| P478 | volume | 32 |
| Q35897912 | A Randomized, Double-blind, Placebo-controlled Trial of Celecoxib Augmentation of Sertraline in Treatment of Drug-naive Depressed Women: A Pilot Study |
| Q48063321 | A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression |
| Q39977947 | A meta-analysis of chemokines in major depression |
| Q37972855 | A neuroimmunological perspective on anxiety disorders. |
| Q37395509 | A potential role for pro-inflammatory cytokines in regulating synaptic plasticity in major depressive disorder |
| Q37725843 | A psychoneuroimmunological review on cytokines involved in antidepressant treatment response |
| Q48468840 | ATP-binding cassette sub-family F member 1 (ABCF1) is identified as a putative therapeutic target of escitalopram in the inflammatory cytokine pathway |
| Q58082651 | Abnormal protein and mRNA expression of inflammatory cytokines in the prefrontal cortex of depressed individuals who died by suicide |
| Q38349600 | Adolescent-Onset Depression: Are Obesity and Inflammation Developmental Mechanisms or Outcomes? |
| Q38167857 | An intricate relationship between pain and depression: clinical correlates, coactivation factors and therapeutic targets |
| Q42087210 | Anti-inflammatory Effect of Amitriptyline on Ulcerative Colitis in Normal and Reserpine-Induced Depressed Rats |
| Q41811660 | Anti-inflammatory effects of antidepressant and atypical antipsychotic medication for the treatment of major depression and comorbid arthritis: a case report |
| Q40156599 | Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. |
| Q88815633 | Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder |
| Q34626598 | Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness |
| Q57700286 | Assessment of Translocator Protein Density, as Marker of Neuroinflammation, in Major Depressive Disorder: A Pilot, Multicenter, Comparative, Controlled, Brain PET Study (INFLADEP Study) |
| Q35844355 | Association of depressive disorders, depression characteristics and antidepressant medication with inflammation |
| Q39646523 | Beneficial Effects of Maprotiline in a Murine Model of Colitis in Normal and Reserpinised Depressed Rats |
| Q92376981 | Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies |
| Q47555879 | Blood-based biomarkers predicting response to antidepressants. |
| Q38381010 | Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial |
| Q37032660 | Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. |
| Q47709549 | Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis |
| Q35871861 | Circulating microRNA-144-5p is associated with depressive disorders |
| Q48747550 | Citalopram protects against cold-restraint stress-induced activation of brain-derived neurotrophic factor and expression of nuclear factor kappa-light-chain-enhancer of activated B cells in rats |
| Q34480323 | Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder |
| Q38154918 | Cytokines as biomarkers in depressive disorder: current standing and prospects. |
| Q37201357 | DNA methylation in interleukin-11 predicts clinical response to antidepressants in GENDEP |
| Q44297143 | Depression contributed an unsatisfactory surgery outcome among the posterior decompression of the cervical spondylotic myelopathy patients: a prospective clinical study |
| Q35638534 | Depression in patients with rheumatoid arthritis: description, causes and mechanisms |
| Q33626044 | Depressive symptoms during rehabilitation period predict poor outcome of lumbar spinal stenosis surgery: a two-year perspective |
| Q38901511 | Does Diet Matter? The Use of Polyunsaturated Fatty Acids (PUFAs) and Other Dietary Supplements in Inflammation-Associated Depression |
| Q41881617 | Effect of Ondansetron, a 5-HT(3) receptor antagonist, on fatigue in 2 veterans with hepatitis C. |
| Q90299327 | Effect of selective serotonin reuptake inhibitor on prefrontal-striatal connectivity is dependent on the level of TNF-α in patients with major depressive disorder |
| Q38565570 | Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? |
| Q38831882 | Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD. |
| Q55499462 | Exploration of 27 plasma immune markers: a cross-sectional comparison of 64 old psychiatric inpatients having unipolar major depression and 18 non-depressed old persons. |
| Q35356872 | Functional biomarkers of depression: diagnosis, treatment, and pathophysiology |
| Q28396103 | Immune and Neuroendocrine Mechanisms of Stress Vulnerability and Resilience |
| Q34997238 | Immunity, aging, and geriatric depression |
| Q33631013 | Impact of sertraline on serum concentration of CRP in hemodialysis patients with depression |
| Q37310533 | Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment. |
| Q53445070 | Inflammation and Improvement of Depression Following Electroconvulsive Therapy in Treatment-Resistant Depression. |
| Q90953794 | Inflammation and the dimensions of depression: A review |
| Q35046651 | Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression |
| Q36889327 | Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression |
| Q37196099 | Inflammation, glutamate, and glia in depression: a literature review. |
| Q35023431 | Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES) |
| Q37047749 | Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. |
| Q97519980 | Inflammation-Associated Synaptic Alterations as Shared Threads in Depression and Multiple Sclerosis |
| Q34493536 | Inflammation: depression fans the flames and feasts on the heat |
| Q33620656 | Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users |
| Q38208771 | Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors |
| Q89955784 | Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5,166 patients and 5,083 controls |
| Q28070891 | Integrating Interleukin-6 into depression diagnosis and treatment |
| Q34026599 | Labile anger during interferon alfa treatment is associated with a polymorphism in tumor necrosis factor alpha |
| Q37092101 | Leukocyte telomere length predicts SSRI response in major depressive disorder: A preliminary report |
| Q48057103 | Levels of C-reactive protein (CRP) in elderly patients with unipolar depression - case control analysis. |
| Q48154622 | Levels of C-reactive protein (CRP) in patients with schizophrenia, unipolar depression and bipolar disorder |
| Q39124105 | Low IL-8 is associated with anxiety in suicidal patients: genetic variation and decreased protein levels. |
| Q92238252 | Low-Grade Inflammation as a Predictor of Antidepressant and Anti-Inflammatory Therapy Response in MDD Patients: A Systematic Review of the Literature in Combination With an Analysis of Experimental Data Collected in the EU-MOODINFLAME Consortium |
| Q43131864 | Milnacipran treatment and potential biomarkers in depressed patients following an initial SSRI treatment failure: a prospective, open-label, 24-week study. |
| Q58614654 | Moderators for depressed mood and systemic and transcriptional inflammatory responses: a randomized controlled trial of endotoxin |
| Q38764226 | Modulatory Effects of Antidepressant Classes on the Innate and Adaptive Immune System in Depression. |
| Q34369407 | Neuroimmune mechanisms of cytokine-induced depression: current theories and novel treatment strategies. |
| Q90344807 | Neuroinflammation in Bipolar Depression |
| Q38317241 | Novel investigational drugs targeting IL-6 signaling for the treatment of depression |
| Q35984653 | Optimizing the Exercise Prescription for Depression: The Search for Biomarkers of Response |
| Q92710468 | Peripheral cytokine levels and response to antidepressant treatment in depression: a systematic review and meta-analysis |
| Q37348823 | Plasma Levels of IL-23 and IL-17 before and after Antidepressant Treatment in Patients with Major Depressive Disorder |
| Q91669926 | Preventive Effects of Escitalopram Against Anxiety-Like Depressive Behaviors in Monosodium Glutamate-Teated Rats Subjected to Partial Hepatectomy |
| Q36438114 | Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder |
| Q64244337 | Psychobiological factors of resilience and depression in late life |
| Q93104581 | Relationship between the Intake of n-3 Polyunsaturated Fatty Acids and Depressive Symptoms in Elderly Japanese People: Differences According to Sex and Weight Status |
| Q36576591 | Serotonin reuptake inhibitor antidepressants (SSRIs) against atherosclerosis. |
| Q37453252 | Serum Cytokine Levels in Major Depressive Disorder and Its Role in Antidepressant Response |
| Q37562443 | Sirukumab: A Potential Treatment for Mood Disorders? |
| Q21245291 | So depression is an inflammatory disease, but where does the inflammation come from? |
| Q36067322 | Somatic drugs for psychiatric diseases: aspirin or simvastatin for depression? |
| Q37911004 | Surrogate markers of treatment outcome in major depressive disorder |
| Q94464760 | Targeting Inflammatory-Mitochondrial Response in Major Depression: Current Evidence and Further Challenges |
| Q93334893 | The Impact of Stress and Major Depressive Disorder on Hippocampal and Medial Prefrontal Cortex Morphology |
| Q26783012 | The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments |
| Q64892118 | The Role of Chemokines in the Pathophysiology of Major Depressive Disorder. |
| Q92405241 | The Role of Inflammation in Depression and Fatigue |
| Q37281155 | The association between immune activation and manic symptoms in patients with a depressive disorder. |
| Q35356649 | The effect of antidepressant medication treatment on serum levels of inflammatory cytokines: a meta-analysis |
| Q35177870 | The inflammation hypothesis in geriatric depression |
| Q38187699 | The inflammatory cytokines: molecular biomarkers for major depressive disorder? |
| Q35731801 | The mechanisms by which antidepressants may reduce coronary heart disease risk |
| Q36524243 | The pro-inflammatory profile of depressed patients is (partly) related to obesity |
| Q38651269 | The renin-angiotensin system: a possible new target for depression |
| Q55163955 | The role of neuroinflammation and neurovascular dysfunction in major depressive disorder. |
| Q47785792 | Therapeutic strategies for treatment of inflammation-related depression. |
| Q43188680 | Thyroid autoimmunity and treatment response to escitalopram in major depression |
| Q36905880 | Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression |
| Q36583311 | Treating depression and depression-like behavior with physical activity: an immune perspective |
| Q37820728 | Understanding the role of inflammatory-related pathways in the pathophysiology and treatment of psychiatric disorders: evidence from human peripheral studies and CNS studies |
| Q21245293 | Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile |
| Q48071032 | Youth Depression Alleviation-Augmentation with an anti-inflammatory agent (YoDA-A): protocol and rationale for a placebo-controlled randomized trial of rosuvastatin and aspirin. |
Search more.